Research programme: CNS disorder therapy - IMPAX Laboratories/Intec Pharma

Drug Profile

Research programme: CNS disorder therapy - IMPAX Laboratories/Intec Pharma

Latest Information Update: 25 Oct 2015

Price : $50

At a glance

  • Originator IMPAX Laboratories; Intec Pharma
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Neurological disorders

Most Recent Events

  • 22 Oct 2015 Intec Pharma has patent protection for Accordion Pill platform in Europe
  • 27 Jun 2006 Preclinical trials in Neurological disorders in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top